Expression of Tumor Necrosis Factor-α in Prostate Cancer and Its Clinical Significance_West China Medical Journal

Authors：

 XURui ¹ , CHENXu ² , WANGLi ¹ , LIUKai-ge ¹ , CHENGBi-ping ³

1. Research Department;Affiliated Hospital of Xi'an Medical University, Xi'an, Shaanxi 710077, P. R. China;
Nursing Department;Affiliated Hospital of Xi'an Medical University, Xi'an, Shaanxi 710077, P. R. China;
3. Department of Key Laboratory;Affiliated Hospital of Xi'an Medical University, Xi'an, Shaanxi 710077, P. R. China;

Corresponding?author：

Keywords：

Prostate cancer; Tumor necrosis factor-α; Microvessel density

DOI：

10.7507/1002-0179.20150121

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Objective To investigate the expression of tumor necrosis factor-α (TNF-α) in prostate cancer tissue and explore its relations with tumor angiogenesis. Methods The expression of TNF-α and CD105 were detected with two-step immunohistochemical staining technique in 20 cases of benign prostatic hyperplasia and 50 cases of prostate cancer between January 2010 and January 2012, and microvessel density (MVD) marked with CD105 was also measured. Results The expressions of TNF-α and CD105 were higher in prostate cancer (41.72±8.67, 20.15±2.67) than those in benign prostatic hyperplasia (21.01±3.85, 4.34±1.67) (t'=13.990, P<0.001; t'=29.771, P<0.001). TNF-α and MVD were not correlated with age and size of tumor, but were positively correlated with tumor differentiation degree (r_s=0.847, P<0.001; r_s=0.776, P<0.001) and negatively correlated with clinical grades (r_s=-0.769, P<0.001; r_s=-0.842, P<0.001). Conclusion The result indicates that over expression of TNF-α exists in prostate cancer. It may play an important role in the anginogenesis and carcinogenesis of prostate cancer.

Citation： XURui, CHENXu, WANGLi, LIUKai-ge, CHENGBi-ping. Expression of Tumor Necrosis Factor-α in Prostate Cancer and Its Clinical Significance. West China Medical Journal, 2015, 30(3): 407-410. doi: 10.7507/1002-0179.20150121 Copy

1.	Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013[J]. CA Cancer J Clin, 2013, 63(1):11-30.
2.	王晉龍, 白鐵男, 胡海龍, 等. HIF-1α和VEGF-C在前列腺癌中的表達及意義[J]. 天津醫藥, 2012, 40(1):4-6, 98.
3.	Prévost-Blondel A, Roth E, Rosenthal FM, et al. Crucial role of TNF-alpha in CD8 T cell-mediated elimination of 3LL-A9 Lewis lung carcinoma cells in vivo[J]. J Immmunol, 2000, 164(7):3645-3651.
4.	Baxevanis CN, Voutsas IF, Tsitsilonis OE, et al. Compromised anti-tumor responses in tumor necrosis factor-alpha knockout mice[J]. Eur J Immunol, 2000, 30(7):1957-1966.
5.	王弱, 劉愛東, 龐久玲, 等. CD105在結直腸腺癌組織中的表達及意義[J]. 山東醫藥, 2007, 47(20):27.
6.	Egevad L, Granfors T, Karlberg L, et al. Prognostic value of the Gleason score in prostate cancer[J]. BJU Int, 2002, 89(6):538-542.
7.	Whitmore WF Jr. Natural history and staging of prostate cancer[J]. Urol Clin North Am, 1984, 11(2):205-210.
8.	Weidner N, Folkman J, Pozza F, et al. Tumor angiogenesis:a new significant and independent prognostic indicator in early-stage breast carcinoma[J]. J Natl Cancer Inst, 1992, 84(17):1875-1887.
9.	崔力方, 郭曉靜, 付麗. TNF-α與腫瘤發生發展關系的研究進展[J]. 中華乳腺病雜志:電子版, 2007, 1(6):236-240.
10.	楊路亭, 鄒玉安, 吳曉萱, 等. TNFα在進展期胃癌局部組織中的分布及意義[J]. 世界華人消化雜志, 2000, 8(增刊1):84.
11.	信濤, 徐玉清, 姜秋穎, 等. TNFα和Bcl-2在大腸癌中的表達及意義[J]. 中國現代醫學雜志, 2003(13):87-89.
12.	Karayiannakis AJ, Syrigos KN, Polychronidis A, et al. Serum levels of tumor necrosis factor-alpha and nutritional status in pancreatic cancer patients[J]. Anticancer Res, 2001, 21(2B):1355-1358.
13.	Yoshida N, Ikemoto S, Narita K, et al. Interleukin-6, tumour necrosis factor alpha and interleukin-1 beta in patients with renal cell carcinoma[J]. Br J Cancer, 2002, 86(9):1396-1400.
14.	趙文鵬, 苗戰會, 路平, 等. TNF-α基因多態性與食管癌相關性的研究[J]. 中國醫療前沿, 2010, 5(7):6-8.
15.	白莉, 毛高平, 曹傳平, 等. 肝癌切除術后轉移過程中炎性遞質的作用[J]. 世界華人消化雜志, 2005, 13(13):1507-1509.
16.	Durkan GC, Nutt JE, Marsh C, et al. Alteration in urinary matrix metalloproteinase-9 to tissue inhibitor of metalloproteinase-1 ratio predicts recurrence in nonmuscle-invasive bladder cancer[J]. Clin Cancer Res, 2003, 9(7):2576-2582.
17.	Sier CF, Casetta G, Veheijen JH, et al. Enhanced urinary gelatinase activities (matrix metalloproteinases 2 and 9) are associated with early-stage bladder carcinoma:a comparison with clinically used tumor markers[J]. Clin Cancer Res, 2000, 6(6):2333-2340.
18.	王艷芬, 丁永玲, 李家馭, 等. Ang-2、CD105和CD34在腦膠質瘤中的表達及生物學意義[J]. 現代腫瘤醫學, 2008, 16(1):23-26.
19.	張少華, 劉凱歌, 鄭建云, 等. 上皮性卵巢癌中癌胚抗原相關細胞黏附分子1和CD105的表達[J]. 新鄉醫學院學報, 2012, 29(11):834-836.

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013[J]. CA Cancer J Clin, 2013, 63(1):11-30.
2. 王晉龍, 白鐵男, 胡海龍, 等. HIF-1α和VEGF-C在前列腺癌中的表達及意義[J]. 天津醫藥, 2012, 40(1):4-6, 98.
3. Prévost-Blondel A, Roth E, Rosenthal FM, et al. Crucial role of TNF-alpha in CD8 T cell-mediated elimination of 3LL-A9 Lewis lung carcinoma cells in vivo[J]. J Immmunol, 2000, 164(7):3645-3651.
4. Baxevanis CN, Voutsas IF, Tsitsilonis OE, et al. Compromised anti-tumor responses in tumor necrosis factor-alpha knockout mice[J]. Eur J Immunol, 2000, 30(7):1957-1966.
5. 王弱, 劉愛東, 龐久玲, 等. CD105在結直腸腺癌組織中的表達及意義[J]. 山東醫藥, 2007, 47(20):27.
6. Egevad L, Granfors T, Karlberg L, et al. Prognostic value of the Gleason score in prostate cancer[J]. BJU Int, 2002, 89(6):538-542.
7. Whitmore WF Jr. Natural history and staging of prostate cancer[J]. Urol Clin North Am, 1984, 11(2):205-210.
8. Weidner N, Folkman J, Pozza F, et al. Tumor angiogenesis:a new significant and independent prognostic indicator in early-stage breast carcinoma[J]. J Natl Cancer Inst, 1992, 84(17):1875-1887.
9. 崔力方, 郭曉靜, 付麗. TNF-α與腫瘤發生發展關系的研究進展[J]. 中華乳腺病雜志:電子版, 2007, 1(6):236-240.
10. 楊路亭, 鄒玉安, 吳曉萱, 等. TNFα在進展期胃癌局部組織中的分布及意義[J]. 世界華人消化雜志, 2000, 8(增刊1):84.
11. 信濤, 徐玉清, 姜秋穎, 等. TNFα和Bcl-2在大腸癌中的表達及意義[J]. 中國現代醫學雜志, 2003(13):87-89.
12. Karayiannakis AJ, Syrigos KN, Polychronidis A, et al. Serum levels of tumor necrosis factor-alpha and nutritional status in pancreatic cancer patients[J]. Anticancer Res, 2001, 21(2B):1355-1358.
13. Yoshida N, Ikemoto S, Narita K, et al. Interleukin-6, tumour necrosis factor alpha and interleukin-1 beta in patients with renal cell carcinoma[J]. Br J Cancer, 2002, 86(9):1396-1400.
14. 趙文鵬, 苗戰會, 路平, 等. TNF-α基因多態性與食管癌相關性的研究[J]. 中國醫療前沿, 2010, 5(7):6-8.
15. 白莉, 毛高平, 曹傳平, 等. 肝癌切除術后轉移過程中炎性遞質的作用[J]. 世界華人消化雜志, 2005, 13(13):1507-1509.
16. Durkan GC, Nutt JE, Marsh C, et al. Alteration in urinary matrix metalloproteinase-9 to tissue inhibitor of metalloproteinase-1 ratio predicts recurrence in nonmuscle-invasive bladder cancer[J]. Clin Cancer Res, 2003, 9(7):2576-2582.
17. Sier CF, Casetta G, Veheijen JH, et al. Enhanced urinary gelatinase activities (matrix metalloproteinases 2 and 9) are associated with early-stage bladder carcinoma:a comparison with clinically used tumor markers[J]. Clin Cancer Res, 2000, 6(6):2333-2340.
18. 王艷芬, 丁永玲, 李家馭, 等. Ang-2、CD105和CD34在腦膠質瘤中的表達及生物學意義[J]. 現代腫瘤醫學, 2008, 16(1):23-26.
19. 張少華, 劉凱歌, 鄭建云, 等. 上皮性卵巢癌中癌胚抗原相關細胞黏附分子1和CD105的表達[J]. 新鄉醫學院學報, 2012, 29(11):834-836.

Previous Article
主動脈夾層動脈瘤支架置入術中血鉀濃度異常增高二例
Next Article
Anticancer Effect of Ginsenoside Rg3 on Mice Colorectal Cancer

West China Medical Journal

Expression of Tumor Necrosis Factor-α in Prostate Cancer and Its Clinical Significance

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content